Abstract: A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed.

Abstract: Apparatus and method for data security in a data storage environment. In some embodiments, input data from a host is received into a buffer memory. Data compression is applied to the input data to provide compressed data. Encryption is applied to the compressed data to generate encrypted data, and the encrypted data are stored in a main memory of a data storage device. A system parameter value associated with the storage of the encrypted data is generated and stored in a memory, such as the main memory of the storage device. The system parameter value may include information relating to the compression of the data. A trusted relationship is established to authenticate the host responsive to a request for the updated system parameter value. The system parameter value is transferred to the host responsive to the established trusted relationship.

Abstract: A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed.

Abstract: A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed.

Abstract: Apparatus and method for data security in a data storage environment. In some embodiments, input data from a host is received into a buffer memory. Data compression is applied to the input data to provide compressed data. Encryption is applied to the compressed data to generate encrypted data, and the encrypted data are stored in a main memory of a data storage device. A system parameter value associated with the storage of the encrypted data is generated and stored in a memory, such as the main memory of the storage device. The system parameter value may include information relating to the compression of the data. A trusted relationship is established to authenticate the host responsive to a request for the updated system parameter value. The system parameter value is transferred to the host responsive to the established trusted relationship.

Abstract: Systems or methods can be used to detect evidence of tampering. The tampering can be physical tampering, such as the turning of a screw, or removal or modification of an electronic component. In some examples, a tamper detection value can be determined from a tamper detection device and compared to a predetermined tamper detection value to determine if tampering is indicated. The system can, upon detection of the tampering, halt an operation, disable device or circuit functionality, disable future operations, physically disable a device, or any combination thereof.

Abstract: A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed.

Abstract: A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed.

Abstract: A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed.